<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735410</url>
  </required_header>
  <id_info>
    <org_study_id>V44P12S</org_study_id>
    <secondary_id>2008-000887-18</secondary_id>
    <nct_id>NCT00735410</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009</brief_title>
  <official_title>A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2008/2009 When Administered to Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Annual trial for registration influenza vaccine with the strain composition for season
      2008/2009
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21</measure>
    <time_frame>21 days (-1/+7)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety of the influenza vaccine</measure>
    <time_frame>21 days (-1/+7)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Seasonal Influenza, Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Influenza Vaccine</intervention_name>
    <description>1 dose of Split influenza vaccine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age, mentally competent, willing and able to give informed consent prior
             to study entry

          -  available for all the visits scheduled in the study and able to comply with all study
             requirements

          -  in good health as determined by: medical history physical examination clinical
             judgment of the investigator

        Exclusion Criteria:

          -  They Have any serious (in the judgment of the investigator) disease, including but not
             limited to:

        Cancer, except for localized skin cancer Advanced congestive heart failure Chronic
        obstructive pulmonary disease (COPD) Autoimmune disease (including rheumatoid arthritis)
        Acute or progressive hepatic disease Acute or progressive renal disease Severe neurological
        or psychiatric disorder Severe Asthma

          -  They have a history of any anaphylactic reaction and/or serious allergic reaction
             following a vaccination, a proven hypersensitivity to any component of the study
             vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral
             protein neomycin or polymyxin).

          -  Known or suspected (or have a high risk of developing) impairment/alteration of immune
             function (excluding that normally associated with advanced age) resulting for example
             from:

        receipt of immunosuppressive therapy (any parental or oral cortical steroid or cancer
        chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
        Receipt of immunostimulants, Receipt of parenteral immunoglobulin preparation, blood
        products, and/or plasma derivatives within the past 3 months and for the full length of the
        study, Suspected or known HIV infection or HIV-related disease.

          -  Known or suspected history of drug or alcohol abuse.

          -  They have a bleeding diathesis or conditions associated with prolonged bleeding time
             that in the investigator's opinion would interfere with the safety of the subject;

          -  Women who are pregnant or woman of childbearing potential unwilling to practice
             acceptable contraception for the duration of the study (21 days).

          -  Influenza vaccination or laboratory confirmed influenza within the last 6 months and
             more than one influenza vaccination within the past 12 months

          -  Within the past 4 weeks they have received:

        another vaccine any investigational agent;

          -  Any acute or chronic infection requiring systemic antibiotic treatment or antiviral
             therapy within the last 7 days.

          -  They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days

          -  Simultaneous participation in another clinical study.

          -  Any condition, which, in the opinion of the investigator, might prevent the subject
             from participation or interfere with the evaluation of the study objectives.

          -  Severely obese with Body Mass Index (BMI) &gt; 35

          -  Site personnel involved in evaluation of safety and their immediate relatives are
             excluded from participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1, 2 and 3</name>
      <address>
        <city>Hessen</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=8563</url>
    <description>Results for V44P12S from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Seasonal</keyword>
  <keyword>Split</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

